Annovis Bio Appoints Hui Liu As New Director Of Biostatistics To Strengthen Data-Driven Drug Development

Annovis Bio Inc., a late-stage clinical drug platform company dedicated to developing innovative treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, has announced the appointment of Hui Liu as Director of Biostatistics. Ms. Liu brings more than 19 years of experience in the design, analysis, and reporting of clinical trials across all phases of development and a wide range of therapeutic areas. Her expertise spans various aspects of statistical methodology, including the creation of statistical analysis plans, development of programming specifications, and interpretation of complex clinical data in support of regulatory filings.

Cheng Fang, Ph.D., Senior Vice President, Research and Development, said in a statement, “Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence. Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move toward our goals.”

Ms. Liu stated, "I’m excited to join Annovis and honored to work with a passionate and driven team. I look forward to applying my statistical expertise to further enhance the integrity of the company’s clinical trials and to help generate high-quality evidence that will support scientific advancement and regulatory success.”

Beyond her technical qualifications, Ms. Liu has a strong background in leadership and project management. She has successfully led high-performing teams, overseen major client accounts, and contributed to strategic initiatives aimed at enhancing operational quality, efficiency, and cross-functional collaboration. Her appointment is expected to strengthen Annovis Bio’s clinical development capabilities as the company advances its pipeline of therapies targeting neurodegenerative disorders.